Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273959 | 0.82 | FDPS (0.32) | FDPS | |
| SCHEMBL17274016 | 0.77 | FDPS (0.35) | FDPS | |
| SCHEMBL5875565 | 0.74 | NOS1 (0.42) | SMN1; SMN2NOS1TSHRALDH1A1HPGD | |
| SCHEMBL22736793 | 0.72 | NOS1 (0.43) | SMN1; SMN2NOS1TSHRALDH1A1HPGD | |
| SCHEMBL17273956 | 0.70 | CCNE2 (0.40) | — | |
| SCHEMBL1095997 | 0.68 | GABRP (0.37) | SMN1; SMN2NOS1 | |
| Hydrochloric Acid SCHEMBL1827565 | 0.68 | GABRP (0.35) | NOS1 | |
| SCHEMBL15733491 | 0.68 | SMN1; SMN2 (0.36) | SMN1; SMN2FDPSNPC1RAB9A | |
| SCHEMBL3188826 | 0.67 | NOS1 (0.46) | SMN1; SMN2NOS1TSHRGAAALDH1A1 | |
| SCHEMBL19261343 | 0.67 | NOS1 (0.38) | SMN1; SMN2NOS1ALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453038-B2 | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | GCK, GCKR, HK2 | SMN1; SMN2 3353/4885NOS1 2128/4885GRM8 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.